Trial Profile
CER-001 Infusions in Subjects with Familial HDL-c Deficiency
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jan 2020
Price :
$35
*
At a glance
- Drugs CER 001 (Primary)
- Indications Tangier disease
- Focus Proof of concept; Therapeutic Use
- Acronyms SAMBA
- Sponsors ABIONYX Pharma; Cerenis Therapeutics
- 03 Sep 2014 Results published in the Media Release.
- 02 Jun 2014 Status changed from recruiting to completed.
- 02 Jun 2014 According to a Cerenis media release, results were presented at the 82nd Congress of the European Atherosclerosis Society.